Mitoksantron: interakcje
Mitoksantron: 34 udokumentowane interakcje w indeksowanych przez nas etykietach FDA i kartach informacyjnych. Poważne: 2, umiarkowane: 9, niewielkie: 23, pary, dla których etykieta nie zgłasza istotnej interakcji: 0. Każda pozycja poniżej cytuje zdanie, na którym się opiera. Ta strona leku to punkt wyjścia, a nie rozstrzygnięcie dla indywidualnej sytuacji.
Interakcje z etykiety
Poważne interakcje (2)
When switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating GILENYA [see Warnings and Precautions (5.2)] . (etykieta leku Fingolimod, Interakcje z innymi lekami)
Coadministration of VOSEVI with BCRP substrates (e.g., methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, rosuvastatin, sulfasalazine, topotecan) is not recommended [see Clinical Pharmacology (12.3) ]. (etykieta leku Sofosbuwir + welpataswir, Interakcje z innymi lekami)
Umiarkowane interakcje (9)
Anthracycline Antibiotics High doses of cyclosporine (e.g., at starting intravenous dose of 16 mg/kg/day) may increase the exposure to anthracycline antibiotics (e.g., doxorubicin, mitoxantrone, daunorubicin) in cancer patients. (etykieta leku Cyklosporyna, Interakcje z innymi lekami)
- DaunorubicynaUmiarkowana
Cardiac Effects Because of the possible danger of cardiac effects in patients previously treated with daunorubicin or doxorubicin, the benefit-to-risk ratio of mitoxantrone injection therapy in such patients should be determined before starting therapy. (etykieta leku Mitoksantron, Ostrzeżenia)
- DoksorubicynaUmiarkowana
Cardiac Effects Because of the possible danger of cardiac effects in patients previously treated with daunorubicin or doxorubicin, the benefit-to-risk ratio of mitoxantrone injection therapy in such patients should be determined before starting therapy. (etykieta leku Mitoksantron, Ostrzeżenia)
…(e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP) (e.g., imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, rosuvastatin, sulfasalazine, topotecan). (etykieta leku Eltrombopag, Interakcje z innymi lekami)
Among 112 patients evaluable for safety on the mitoxantrone injection + hydrocortisone arm of the CALGB trial, 18 patients (19%) had a reduction in cardiac function, 5 patients (5%) had cardiac ischemia, and 2 patients (2%) experienced pulmonary edema. (etykieta leku Mitoksantron, Ostrzeżenia)
For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while… (etykieta leku Leflunomid, Interakcje z innymi lekami)
When switching from drugs with prolonged immune effects, such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone, consider the duration and mode of action of these drugs because of additive immunosuppressive effects when initiating OCREVUS [see Warnings and Precautions (5.2) ]. (etykieta leku Okrelizumab, Interakcje z innymi lekami)
In a randomized comparative trial of mitoxantrone injection plus low-dose prednisone vs. low-dose prednisone, 7 of 128 patients (5.5 %) treated with mitoxantrone injection had a cardiac event defined as any decrease in LVEF below the normal range, congestive heart failure (n = 3), or myocardial ischemia. (etykieta leku Mitoksantron, Ostrzeżenia)
For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while… (etykieta leku Teryflunomid, Interakcje z innymi lekami)
Wzmianki o niewielkim znaczeniu (23)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etykieta leku Mitoksantron, Interakcje z innymi lekami)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etykieta leku Mitoksantron, Interakcje z innymi lekami)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etykieta leku Mitoksantron, Interakcje z innymi lekami)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etykieta leku Mitoksantron, Interakcje z innymi lekami)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etykieta leku Mitoksantron, Interakcje z innymi lekami)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etykieta leku Mitoksantron, Interakcje z innymi lekami)
In first-line comparative trials of mitoxantrone injection + cytarabine vs. daunorubicin + cytarabine in adult patients with previously untreated ANLL, therapy was associated with congestive heart failure in 6.5% of patients on each arm. (etykieta leku Mitoksantron, Ostrzeżenia)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etykieta leku Mitoksantron, Interakcje z innymi lekami)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etykieta leku Mitoksantron, Interakcje z innymi lekami)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etykieta leku Mitoksantron, Interakcje z innymi lekami)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etykieta leku Mitoksantron, Interakcje z innymi lekami)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etykieta leku Mitoksantron, Interakcje z innymi lekami)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etykieta leku Mitoksantron, Interakcje z innymi lekami)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etykieta leku Mitoksantron, Interakcje z innymi lekami)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etykieta leku Mitoksantron, Interakcje z innymi lekami)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etykieta leku Mitoksantron, Interakcje z innymi lekami)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etykieta leku Mitoksantron, Interakcje z innymi lekami)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etykieta leku Mitoksantron, Interakcje z innymi lekami)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etykieta leku Mitoksantron, Interakcje z innymi lekami)
• Prior treatment with an immunosuppressant (e.g., mitoxantrone, azathioprine, methotrexate, cyclophosphamide, mycophenolate mofetil). (etykieta leku Natalizumab, Ostrzeżenia i środki ostrożności)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etykieta leku Mitoksantron, Interakcje z innymi lekami)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etykieta leku Mitoksantron, Interakcje z innymi lekami)
Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etykieta leku Mitoksantron, Interakcje z innymi lekami)
Sprawdź, jak Mitoksantron łączy się ze wszystkim, co przyjmujesz. Dodaj całą listę; wszystkie pary są sprawdzane jednocześnie.
Otwórz w wyszukiwarceTo nie jest porada medyczna. Stopień nasilenia odzwierciedla sformułowania etykiety, a nie indywidualne okoliczności. Oznaczenie „poważna” może dotyczyć połączenia stosowanego rutynowo pod nadzorem, a „niewielka” może mieć znaczenie przy dużych dawkach. Należy zapytać farmaceutę.